Search

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: miRNA-194 were knocked down or overexpressed in Osteosarcoma Cell Line SOSP-9607 to investigate its effect on Metastasis of human Osteosarcoma which to provide the foundation of theory of miRNA-194 as a new target of osteosarcoma therapy. Methods: We transfected human osteosarcoma cell lines SOSP-9607 by using recombinant lentiviruses and divided the cells into three groups with different levels of miRNA-194. Then the stable transfected cells were used in transwell and wound healing assay. Results:1) The transfection and selection of miRNA-194 using recombinant lentiviral expression vector was finished correctly and different levels of miRNA-194 were got sucessfully. 2) Results in the transwell migration and invasion assay showed significantly lower numbers of OE SOSP-9607 cells (28.60± 4.36) and (21.25± 6.42) and significantly higher numbers of KD SOSP-9607 cells (132.60± 15.64; 115.76± 11.38) compared with other groups (p<0.05). The wound healing assay showed that cells in OE groups exhibited a significant decrease in migration rate compared to the other three groups(p<0.05). Conclusions: miRNA-194 could inhibit metastasis of Osteosarcoma Cell Line SOSP-9607. MiRNA-194 could be further explored as a potential target in Osteosarcoma diagnosis and therapy. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)